Ganciclovir

C. diff Risk

None

Oral Bioavailability

NA

Dosing

Treatment/induction dose: 5 mg/kg IV q12hProphylaxis/maintenance dose: 5 mg/kg IV q24h

70+ mL/min50 - 69 mL/min25 - 49 mL/min10 - 24 mL/min0 - 10 mL/min5 mg/kg IV q12h2.5 mg/kg IV q12h2.5 mg/kg IV q24h
1.25 mg/kg IV q24h1.25 mg/kg IV 3 times weekly

70+ mL/min50 - 69 mL/min25 - 49 mL/min10 - 24 mL/min0 - 10 mL/min5 mg/kg IV q24h2.5 mg/kg IV q24h1.25 mg/kg IV q24h0.625 mg/kg IV q24h0.625 mg/kg IV 3 times weekly

Treatment/induction Dose:
1.25 mg/kg IV qHD - give after dialysis on dialysis days

Prophylaxis/maintenance dose:
0.625 mg/kg IV qHD - give after dialysis on dialysis days

Treatment/induction Dose:
2.5 mg/kg IV q12h

Prophylaxis/maintenance dose:
2.5 mg/kg IV q24h

General Information

Adverse Effects

-May cause blood dyscrasias: granulocytopenia, anemia, and thrombocytopenia. Usually within first 1-2 weeks of treatment. Generally resolves within 3-7 days of discontinuation.

Common Usage

CMV infections

Drug Monitoring

CBC with differential twice weekly. Serum creatinine once weekly.

Pharmacology

Antimicrobial class: Antiviral, binds DNA polymerase to inhibit viral DNA synthesis.

Pregnancy category: C - animal studies have demonstrated carcinogenic and teratogenic effects.